iQone Healthcare Holding

What iQone Healthcare Holding does

iQone Healthcare Holding, operating commercially as iQone Healthcare Switzerland SA, is a Swiss specialty pharmaceutical company founded in 2012 and headquartered in Versoix (canton of Geneva). Its core business is the commercialization and distribution of biosimilars and innovative rare-disease treatments in the Swiss market. The company carries a portfolio of 13 Swissmedic-approved biosimilars spanning oncology (Herzuma/trastuzumab, Vegzelma/bevacizumab, Truxima/rituximab, Grasustek/pegfilgrastim), onco-haematology, rheumatology and gastroenterology (Remsima/infliximab IV, Veblocema/infliximab SC, Yuflyma/adalimumab), pneumology, allergology, dermatology (Steqeyma/ustekinumab, Avtozma/tocilizumab, Stoboclo and Osenvelt/denosumab, Omlyclo/omalizumab), and the immunosuppressant Idefirix (imlifidase) for kidney transplant desensitization.

The company does not conduct drug discovery or manufacturing; its technical competency lies in Swissmedic regulatory navigation, cold chain logistics, and the commercial infrastructure required to bring complex biologic products to Swiss hospitals, physicians, and pharmacies. The portfolio is sourced primarily from manufacturing partner Celltrion Healthcare (a South Korean biosimilars leader with FDA cGMP and EMA GMP facilities), supplemented by USV Private Limited (2020) and Hansa Biopharma (2023) partnerships. iQone operates a dedicated Swiss field force segmented by therapeutic area, complemented by a distribution partnership with Avosano Industrie Service AG for ordering and fulfillment, and uses a 'iQone for You' service model offering next-day delivery, cold chain continuity, and dedicated account contacts. In November 2024, Celltrion acquired iQone as a wholly owned subsidiary, with the iQone brand, Versoix headquarters, and existing management team retained for continuity. The company is positioned as the #3 player in the Swiss biosimilars market per IQVIA SDU Volume 2023, behind two global pharmaceutical giants.

The revenue model combines biosimilar product sales (transaction-based) with specialty distribution and market access services for partner manufacturers seeking Swiss entry (regulatory support, pricing/reimbursement, sales, medical affairs, pharmacovigilance, and quality assurance). Pricing is governed by Swiss federal regulation requiring biosimilars to be priced at least 25% below reference biologics, with reimbursement on the Specialties List under the same terms as originators. Customers are Swiss healthcare professionals, hospitals, and pharmacies across multiple therapeutic areas; named enterprise relationships include Celltrion (manufacturing partner and now parent), Avosano (distribution), and individual HCP and gastroenterology specialist testimonials.

Name

iQone Healthcare Holding

Legal name

iQone Healthcare Switzerland SA

Website

https://iqone-healthcare.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

iQone Healthcare Switzerland is a Swiss specialty pharmaceutical company that commercializes and distributes a portfolio of 13 biosimilar and rare-disease products to hospitals, physicians, and pharmacies across Switzerland, operating as a wholly owned Celltrion subsidiary.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals - Biosimilars Distribution

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAAAD

Immunology & Inflammation Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Specialty pharmaceuticals
• Biosimilar distribution
• Oncology therapies
• Rare disease treatments
• Pharmaceutical commercialization

Headquarters

HQ city

Versoix

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Biosimilar Product Sales: iQone generates revenue through the sale of biosimilar pharmaceutical products to healthcare professionals, hospitals, and pharmacies in Switzerland. Products are sourced primarily from Celltrion Healthcare and supplemented by partnerships with USV Private Limited and Hansa Biopharma.
2. Specialty Distribution Services: Revenue derived from distribution and commercialization services for partner manufacturers seeking market access in Switzerland, including regulatory support, pricing/reimbursement negotiations, sales and marketing, medical affairs, and pharmacovigilance.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

iQone Healthcare Switzerland is a specialty pharmaceutical company that commercializes a portfolio of 13 Swissmedic-approved biosimilars and one orphan immunosuppressant (Idefirix®) across oncology, onco-haematology, rheumatology, gastroenterology, pneumology, allergology, dermatology, and rare diseases in Switzerland. Products are sourced primarily from Celltrion Healthcare and supplemented through partnerships with USV Private Limited and Hansa Biopharma, then sold to healthcare professionals, hospitals, and pharmacies via a direct field sales force and the Avosano wholesale partnership. The "iQone for You" service layer provides tailored support including cold-chain logistics, next-day delivery, training, and pharmacovigilance.

Product overview

iQone Healthcare Switzerland is a specialty pharmaceutical company commercializing biosimilars and innovative treatments for rare diseases in Switzerland. The company operates as a wholly-owned subsidiary of Celltrion following acquisition in November 2024. Its core offering is a portfolio of 13 biosimilar products spanning oncology, onco-haematology, rheumatology, gastroenterology, pneumology, allergology, dermatology, and rare diseases. The products include Anti-TNFα agents (Remsima®, Veblocema®, Yuflyma®), Anti-CD20 therapy (Truxima®), Anti-HER2 (Herzuma®), Anti-VEGF (Vegzelma™), G-CSF (Grasustek®), Anti-IL-12/23 (Steqeyma®), Anti-IL-6R (Avtozma®), RANKL inhibitors (Stoboclo®, Osenvelt®), Anti-IgE (Omlyclo®), and immunosuppressant (Idefirix®). These are complemented by the 'iQone for You' service program providing tailored Swiss-based commercial support, logistics, and market access services.

Differentiator

Problem solved

Functional benefit

Brands

• iQone for You: Service model offering tailored support to healthcare professionals, including dedicated contacts, experienced field force, training, and patient materials.

Products and services

• Steqeyma® (Ustekinumab biosimilar) Anti-IL-12/23 monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for the treatment of inflammatory conditions. Swissmedic authorization number 70003.
• Avtozma® (Tocilizumab biosimilar) Anti-IL-6R monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for inflammatory disease treatment. Swissmedic authorization number 69850.
• Stoboclo® (Denosumab biosimilar - osteoporosis) RANKL inhibitor biosimilar developed by Celltrion and distributed by iQone in Switzerland for osteoporosis treatment. Swissmedic authorization number 70199.
• Osenvelt® (Denosumab biosimilar - oncology) RANKL inhibitor biosimilar developed by Celltrion and distributed by iQone in Switzerland for oncology indications. Swissmedic authorization number 70196.
• Omlyclo® (Omalizumab biosimilar) Anti-IgE monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for chronic allergic and atopic disease treatment.
• Veblocema® (Infliximab SC biosimilar) Anti-TNFα monoclonal antibody biosimilar in subcutaneous formulation, developed by Celltrion and distributed by iQone in Switzerland for inflammatory disease treatment. Swissmedic authorization number 67888.
• Yuflyma® (Adalimumab biosimilar) Anti-TNFα monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for inflammation treatment. Swissmedic authorization number 68514.
• Remsima® (Infliximab IV biosimilar) Anti-TNFα monoclonal antibody biosimilar in intravenous formulation, developed by Celltrion and distributed by iQone in Switzerland for inflammation treatment. Swissmedic authorization number 65373.
• Herzuma® (Trastuzumab biosimilar) Anti-HER2 monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for oncology treatment. Swissmedic authorization number 67892.
• Vegzelma™ (Bevacizumab biosimilar) Anti-VEGF monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for oncology treatment. Swissmedic authorization number 69166. Individual market share reached 69%.
• Truxima® (Rituximab biosimilar) Anti-CD20 monoclonal antibody biosimilar developed by Celltrion and distributed by iQone in Switzerland for inflammation and oncology treatment. Swissmedic authorization number 66648.
• Grasustek® (Pegfilgrastim biosimilar) G-CSF biosimilar developed by Celltrion and distributed by iQone in Switzerland for oncology supportive care. Swissmedic authorization number 68166.
• Idefirix® (Imlifidase) IgG-degrading enzyme immunosuppressant for desensitization in kidney transplantation, distributed by iQone in Switzerland under partnership with Hansa Biopharma. Swissmedic authorization number 68373.
• iQone for You Comprehensive service program providing tailored support for healthcare professionals, including Swiss-based team access, dedicated contacts, experienced field force, training, patient materials, competitive pricing, flexible payment terms, next-day delivery, and cold chain logistics.
• iQone Value Partnership Services Comprehensive market access services for pharmaceutical partners entering the Swiss market, including regulatory approval navigation, marketing strategy, sales, distribution, Medical Affairs, Pharmacovigilance, and Quality Assurance.

Quantifiable outcome

• 679 million CHF in healthcare savings through biosimilars in Switzerland in 2023
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered core and secondary.

• Swiss Patient Access Program (SPAP)coreStrategic or Co-development Partner · 1 January 2025iQone Healthcare Switzerland joined the Swiss Patient Access Program (SPAP) as the third pharmaceutical company and the first biosimilar specialized company as of January 1, 2025. Managed by the Swiss Society of Medical Oncology (SSMO), SPAP addresses critical gaps in patient care by enabling access to treatments not reimbursed by health insurance. iQone provides oncology medications at no cost to eligible cancer patients when not covered by insurance.
• Celltrion HealthcarecoreStrategic or Co-development Partner · 15 November 2024Celltrion Healthcare is iQone's main manufacturing partner and parent company. Celltrion acquired iQone Healthcare Switzerland in November 2024, making it a wholly owned subsidiary. Celltrion is a leading biopharmaceutical company based in Incheon, South Korea, specializing in researching, developing, manufacturing, marketing, and sales of innovative therapeutics including world-class monoclonal antibody biosimilars. Products are manufactured at state-of-the-art mammalian cell culture facilities compliant with US FDA cGMP and EMA GMP standards.
• Hansa BiopharmasecondaryChannel Partner/ Reseller/ Distributor · 1 January 2023Since the beginning of 2023, iQone Healthcare became the registered distributor for the approved Idefirix® (imlifidase) in Switzerland. Idefirix is an immunosuppressant and IgG-degrading enzyme for patients who need organ transplants.
• USV Private LimitedsecondaryStrategic or Co-development Partner · 1 January 2020USV Private Limited is a leading Indian healthcare company with a large portfolio of molecules, recognized as a specialist in research, development, and manufacture of pharmaceutical products. The partnership began in 2020, expanding iQone's network and providing additional therapeutic advances to healthcare professionals in Switzerland. USV shares iQone's focus on excellence and innovation.
• Avosano Industrie Service AGsecondaryChannel Partner/ Reseller/ DistributorAvosano Industrie Service AG is a Swiss pharmaceutical distribution partner handling product ordering and fulfillment for iQone. The partnership involves straightforward information exchange and trust-based collaboration, supporting partners in delivering excellent services to customers.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sandoz: Sandoz is the world's largest biosimilars pure-play, spun out of Novartis in 2023. It competes directly with iQone in the Swiss biosimilar market (likely the #1 or #2 player iQone is benchmarked against) and offers overlapping oncology and immunology biosimilars across European markets.
• Celltrion Healthcare: Celltrion Healthcare is iQone's parent company and the global biosimilar manufacturer whose products (Remsima, Truxima, Herzuma, Yuflyma, etc.) iQone commercializes in Switzerland. It is the upstream counterpart and the most direct biosimilar peer globally.
• Alvotech: Alvotech is a pure-play biosimilar developer with a portfolio of mAb biosimilars targeting immunology and oncology reference products overlapping with iQone's portfolio (e.g., adalimumab, ustekinumab, denosumab). It is a relevant peer for biosimilar commercial strategy and pipeline positioning.
• Samsung Bioepis: Samsung Bioepis develops and commercializes biosimilars in immunology, oncology, and ophthalmology through its Biogen partnership in Europe. It overlaps directly with iQone's product categories and is among the top-tier biosimilar manufacturers competing in European markets.
• Stada Arzneimittel: Stada is a European specialty pharmaceutical company with a growing biosimilars portfolio (including through the Alvotech partnership) and a strong distribution footprint across European markets. It is comparable as a mid-sized European specialty pharma with biosimilar focus.

Broad incumbents

• Pfizer (Biosimilars Division): Pfizer operates one of the largest biosimilars portfolios globally (through Hospira/upjohn legacy assets) and competes in Swiss biosimilar tenders across multiple molecules overlapping with iQone's portfolio. It is a broad incumbent with much larger scale.
• Amgen (Biosimilars): Amgen both develops biosimilars (e.g., Amgevita, Kanjinti) and markets originator biologics, putting it in direct competition with iQone across multiple therapeutic areas in Switzerland. It is a broad incumbent with strong hospital relationships.
• Teva Pharmaceutical Industries: Teva has a global specialty pharmaceutical and biosimilar footprint with European commercial operations that overlap with iQone's therapeutic focus areas. It is a broad incumbent relevant for benchmarking specialty pharma distribution in Switzerland.

Emerging players

• Polpharma Biologics: Polpharma Biologics is an emerging European biosimilar developer with a focused portfolio in immunology and oncology. It is comparable to iQone as a smaller-scale biosimilar player targeting European markets.
• Coherus BioSciences: Coherus is a US-based biosimilar specialist focused on immunology and oncology mAbs with a smaller commercial footprint than top-tier players. It is comparable to iQone as a focused biosimilar commercial organization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/iqone-healthcare-group

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iQone Healthcare Holding